These results suggested that TPs act as a therapeutic agent for obesity, liver inflammation, and fat degeneration via COX-2 and iNOS inhibition, with TNF-α, IL-1β, and IL-6 involvement. The gene discussed is PTGS2; the disease is obesity due to melanocortin 4 receptor deficiency.